HIV Cure Program Releases Initial Clinical Trial Data
July 15, 2021 23:51 ET | Source: American Gene Technologies American Gene Technologies Rockville, Maryland, UNITED STATES
ROCKVILLE, Md., July 15, 2021 (GLOBE NEWSWIRE) American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient s immune cells. The cells are collected by leukapheresis, modified outside the body, then re-infused. Once infused, the cells are expected to durably suppress the virus at undetectable levels without the need for antiretroviral treatment.
/PRNewswire/ American Gene Technologies (AGT), a clinical-stage biotechnology company, announced treatment of the first participant in its Phase I clinical.
LGBT+ Investment Firm Gaingels Joins American Gene Technologies Mission to Cure HIV, and Other Serious Human Diseases
News provided by
Share this article
, an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of AGT103-T, a single dose, autologous cell therapy intended to cure the disease.
This investment places Gaingels alongside private investors who believe deeply in AGT s mission, rapid drug development platform, and gene and cell therapy programs for HIV, cancer, and PKU.